Press release from Companies
Published: 2025-06-02 08:45:00
During the fourth quarter of 2024, Spermosens AB (publ) ("Spermosens" or the "Company") carried out a rights issue of units with preferential rights for existing shareholders, as well as directed issues of units to a number of external investors, existing shareholders, and members of the Company’s Board and management. Both the rights issue and the directed issues included units consisting of shares, warrants of series TO 5, and warrants of series TO 6. In connection with the directed issues, the Company also secured a credit facility under which the lender received warrants of series TO 5 and TO 6 free of charge. The exercise period for the warrants of series TO 5 (the "Warrants") begins today on 2 June 2025 and runs until 16 June 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.0055 per share. Upon full exercise of all 467,740,274 Warrants, the Company will receive approximately SEK 2.6 million before transaction costs. To avoid the Warrants expiring without value, holders must exercise them no later than 16 June 2025. Please note that certain nominees (e.g. banks) may require a response from their clients prior to this deadline. Warrant holders are therefore encouraged to contact their respective nominees (e.g. banks) well in advance of the last day in the exercise period.
Summary of terms and key dates
Exercise of warrants, nominee-registered holders
If the Warrant holder has Warrants held in a custody account, an investment savings account (ISK), or an IPS (nominee-registered ownership), subscription and payment are handled through the nominee, who will provide further instructions on how to proceed with the exercise of Warrants. Warrant holders are advised to contact their respective nominees well in advance of the end of the exercise period for further instructions.
Exercise of warrants, directly registered holders
A subscription form can be requested from Eminova Fondkommission AB via info@eminova.se or by calling +46 8 684 211 00. Payment is made in accordance with the instructions on the subscription form. Both the completed subscription form and payment must be received by Eminova Fondkommission AB no later than the date specified on the form.
As soon as both subscription and payment have been registered by Eminova Fondkommission AB, the Warrants will be replaced with interim shares pending registration with the Swedish Companies Registration Office (Bolagsverket).
Shares, Share Capital, and Dilution
Upon full exercise of the Warrants, the total number of shares may increase by 467,740,274, from 1,356,181,416 to 1,823,921,690, and the share capital may increase by approximately SEK 935,480.55, from approximately SEK 2,712,362.83 to approximately SEK 3,647,843.38, corresponding to a dilution of approximately 25.6 percent of the total number of shares and votes in the Company following registration of the new shares with the Swedish Companies Registration Office.
Eminova Partners Corporate Finance AB acts as financial advisor and Fram Advokatbyrå KB acts as legal advisor in connection with the exercise of the Warrants. Eminova Fondkommission AB acts as issue agent.
Tore Duvold, CEO
info@spermosens.com
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com
